Tech Company M&A Transactions
Potenza Therapeutics Acquisition
Potenza Therapeutics, operating out of Cambridge, was acquired by Astellas Pharma. Astellas Pharma disclosed that the acquisition price was $404.7 million.
Transaction Overview
Company Name
Acquired By
Announced On
12/18/2018
Transaction Type
M&A
Amount
$404,700,000
M&A Terms
Astellas Pharma has acquired Potenza Therapeutics for up to $404.7 million in a deal that bolsters the buyer's cancer immunotherapy pipeline--more than three years after the companies launched an immuno-oncology collaboration that has produced two Phase I candidates and a third candidate bound for the clinic.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
700 Main St. North
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Potenza Therapeutics is focusing on the discovery and development of novel immune-oncology therapeutics: Molecules that stimulate the power of the immune system to fight cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Lisa Velardo
Co-Founder
Peter Parker
Controller
Abby Johnson
President
Johannes Fruehauf
VP - Operations
Krista Licata
VP - Operations
Maggie O'Toole
Browse more venture capital transactions:
Prev: 12/18/2018: SonarMD venture capital transaction
Next: 12/18/2018: DataCamp venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs